Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 29, 2026, 2:39 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1057–1080 of 8,151 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Oral Clear all
Recruiting Phase 4 Interventional

Serial Magnetic Resonance Imaging for the Prediction of Radiation-Induced Changes in Normal Tissue of Patients With Oral Cavity or Skull Base Tumors

NCT04265430
View directory record Official record
Conditions
Malignant Oral Cavity Neoplasm, Malignant Skull Base Neoplasm, Osteoradionecrosis
Interventions
Contrast Agent, Magnetic Resonance Imaging, Quality-of-Life Assessment, Questionnaire Administration
Other · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
425 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2031
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Oct 29, 2026, 2:39 PM EDT
Withdrawn Phase 2 Interventional

IV Acetaminophen in Children Undergoing Palatoplasty

NCT01760330
View directory record Official record
Conditions
Cleft Palate
Interventions
IV acetaminophen, Placebo
Drug
Lead sponsor
Nationwide Children's Hospital
Other
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 8, 2016 · Synced Oct 29, 2026, 2:39 PM EDT
Completed Phase 2 Interventional

HAT in Eye Complications of Behcet's Disease

NCT00001865
View directory record Official record
Conditions
Behcet's Syndrome, Retinal Disease, Uveitis
Interventions
Daclizumab
Drug
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
Not listed
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2004
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 29, 2026, 2:39 PM EDT
Completed Not applicable Interventional Results available

Direct Oral Anticoagulants (DOACs) Versus LMWH +/- Warfarin for VTE in Cancer

NCT02744092
View directory record Official record
Conditions
Cancer, Venous Thromboembolism, Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE), Blood Clot
Interventions
Rivaroxaban, Apixaban, Edoxaban, Dabigatran, Warfarin, Dalteparin, Enoxaparin, Fondaparinux
Drug
Lead sponsor
Alliance Foundation Trials, LLC.
Other
Eligibility
18 Years and older
Enrollment
811 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
151
States / cities
Chula Vista, California • Fremont, California • Fresno, California + 104 more
Source: ClinicalTrials.gov public record
Updated Oct 3, 2023 · Synced Oct 29, 2026, 2:39 PM EDT
Active, not recruiting Phase 4 Interventional

Evaluation of Trigeminal Nerve Blockade

NCT03632044
View directory record Official record
Conditions
Mouth Abnormalities, Cleft Palate, Birth Defect
Interventions
Ropivacaine, Sham Comparator
Drug · Other
Lead sponsor
University of Florida
Other
Eligibility
3 Months to 5 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Oct 29, 2026, 2:39 PM EDT
Terminated Phase 2 Interventional Results available

A Study to Assess the Safety and Efficacy of ZPL389 With TCS/TCI in Atopic Dermatitis Patients

NCT03948334
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
ZPL389 30mg, ZPL389 50mg, TCS and/or TCI
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
2
States / cities
Litchfield Park, Arizona • Fairborn, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 8, 2021 · Synced Oct 29, 2026, 2:39 PM EDT
Terminated Phase 2 Interventional Results available

Incobotulinum Toxin for the Treatment of Trigeminal Neuralgia

NCT02088632
View directory record Official record
Conditions
Trigeminal Neuralgia
Interventions
Incobotulinumtoxina, Placebo Comparator
Biological · Other
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years to 75 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 28, 2023 · Synced Oct 29, 2026, 2:39 PM EDT
Terminated Phase 1 Interventional

Study of GBT021601 in Participants With Renal Impairment

NCT05878704
View directory record Official record
Conditions
Renal Impairment
Interventions
GBT021601
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
4
States / cities
Lake Forest, California • Tustin, California • Miami, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2024 · Synced Oct 29, 2026, 2:39 PM EDT
Completed Phase 2 Interventional

A Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations

NCT05199584
View directory record Official record
Conditions
Solid Tumors With PTCH1 Loss-of-function Mutations
Interventions
ENV-101 (taladegib)
Drug
Lead sponsor
Endeavor Biomedicines, Inc.
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
16
States / cities
Los Angeles, California • Santa Rosa, California • Tampa, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2026 · Synced Oct 29, 2026, 2:39 PM EDT
Completed Phase 2 Interventional Results available

Serum Bovine Immunoglobulin Protein Isolate in Improving Quality of Life and Post-Operative Recovery in Patients With Gynecological Cancer After Undergoing Surgery

NCT01867606
View directory record Official record
Conditions
Female Reproductive Cancer
Interventions
serum-derived bovine immunoglobulin protein isolate, placebo, laboratory biomarker analysis, quality-of-life assessment, questionnaire administration
Biological · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Female only
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 1, 2025 · Synced Oct 29, 2026, 2:39 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Ondansetron HCl Orally Disintegrating Tablets Under Non-Fasting Conditions

NCT00934921
View directory record Official record
Conditions
Healthy
Interventions
Ondansetron, Zofran®
Drug
Lead sponsor
Teva Pharmaceuticals USA
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 21, 2024 · Synced Oct 29, 2026, 2:39 PM EDT
Completed Phase 2 Interventional Results available

Study of Efficacy and Safety of LDE225 in Adult Patients With Relapsed/Refractory Acute Leukemia

NCT01826214
View directory record Official record
Conditions
Acute Leukemias
Interventions
LDE225
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 30, 2016 · Synced Oct 29, 2026, 2:39 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of the Abuse Liability Potential of Samidorphan in Healthy, Non-Dependent, Recreational Opioid Users

NCT02218021
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Samidorphan, Placebo, Oxycodone
Drug
Lead sponsor
Alkermes, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
59 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Dec 2, 2014 · Synced Oct 29, 2026, 2:39 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Assessment of Satiety Following Oral Administration of an Erythritol Sweetened Beverage

NCT02934321
View directory record Official record
Conditions
Satiety in Healthy Volunteers
Interventions
Erythritol, Aspartame
Dietary Supplement
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 40 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Aug 28, 2019 · Synced Oct 29, 2026, 2:39 PM EDT
Completed Not applicable Interventional Results available

Scotchbond Universal Plus Compared to Scotchbond Universal for Posterior Class I & II Restorations With Filtek Universal

NCT05248204
View directory record Official record
Conditions
Cavities of Teeth, Dental Decay
Interventions
Scotchbond™ Universal Plus Adhesive, Scotchbond™ Universal Adhesive
Device
Lead sponsor
Solventum US LLC
Industry
Eligibility
18 Years to 70 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 17, 2025 · Synced Oct 29, 2026, 2:39 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study Assessing the Mass Balance of a Single Oral Dose of [14C] DS-8500a in Healthy Subjects

NCT02790684
View directory record Official record
Conditions
Pharmacokinetics
Interventions
DS-8500a
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years to 60 Years · Male only
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Feb 12, 2019 · Synced Oct 29, 2026, 2:39 PM EDT
Terminated Phase 1 Interventional

RBX7455 Before Surgery for the Treatment of Operable Breast Cancer

NCT04139993
View directory record Official record
Conditions
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Breast Adenocarcinoma, Invasive Breast Carcinoma, Prognostic Stage I Breast Cancer AJCC v8, Prognostic Stage IA Breast Cancer AJCC v8, Prognostic Stage IB Breast Cancer AJCC v8, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8, Triple-Negative Breast Carcinoma
Interventions
Microbiota-based Formulation RBX7455
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Female only
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Oct 4, 2023 · Synced Oct 29, 2026, 2:39 PM EDT
Completed Not applicable Interventional Results available

A Clinical Trial to Evaluate Long-term Efficacy and Safety of Lozenges Containing Lactobacilli Reuteri (Prodentis™) on Gingivitis

NCT01811316
View directory record Official record
Conditions
Gingivitis
Interventions
Probiotics
Other
Lead sponsor
Sunstar Americas
Industry
Eligibility
18 Years to 65 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 7, 2017 · Synced Oct 29, 2026, 2:39 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Safety and Efficacy of Bovine Milk Immunoglobulin Against CS17 and CsbD

NCT00524004
View directory record Official record
Conditions
Travelers' Diarrhea
Interventions
Anti-CsbD Bovine IgG, Placebo, Anti-CS17 Bovin IgG
Biological · Other
Lead sponsor
Johns Hopkins Bloomberg School of Public Health
Other
Eligibility
18 Years to 45 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
2
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 5, 2017 · Synced Oct 29, 2026, 2:39 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Effects of Oral vs. Non-oral Contraceptives on the GH/IGF-1 Axis

NCT02367833
View directory record Official record
Conditions
Bone; Disorder, Development and Growth
Interventions
Combined Oral Contraceptive, Transdermal Contraceptive, Contraceptive Vaginal Ring
Drug
Lead sponsor
Penn State University
Other
Eligibility
18 Years to 30 Years · Female only
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
1
States / cities
University Park, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 9, 2020 · Synced Oct 29, 2026, 2:39 PM EDT
Completed Not applicable Interventional

A Nasal Applicator for the Treatment of Trigeminal Neuralgia

NCT01761604
View directory record Official record
Conditions
Trigeminal Neuralgia
Interventions
Nasal ganglion block for TN
Device
Lead sponsor
Chicago Anesthesia Pain Specialists
Other
Eligibility
18 Years to 80 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 14, 2017 · Synced Oct 29, 2026, 2:39 PM EDT
Completed Phase 2 Interventional Results available

Calcitriol, Physical Activity, and Bone Health in Cancer Survivors

NCT00904033
View directory record Official record
Conditions
Breast Neoplasms, Bone and Bones
Interventions
Calcitriol, Exercise, Multivitamin
Drug · Behavioral · Dietary Supplement
Lead sponsor
University of Rochester
Other
Eligibility
18 Years and older · Female only
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2018
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Apr 23, 2019 · Synced Oct 29, 2026, 2:39 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Bioavailability and Bioequivalence of Two Risdiplam Tablets in Healthy Participants

NCT04718181
View directory record Official record
Conditions
Muscular Atrophy, Spinal
Interventions
risdiplam, omeprazole
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 55 Years
Enrollment
131 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
4
States / cities
Daytona Beach, Florida • Springfield, Missouri • Dallas, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2023 · Synced Oct 29, 2026, 2:39 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Pharmacokinetic Study of Avanfil in Healthy Young Male Subjects

NCT00914511
View directory record Official record
Conditions
Avanfil ADME, Semen Exposure, Sperm Function
Interventions
avanafil 200mg
Drug
Lead sponsor
VIVUS LLC
Industry
Eligibility
18 Years and older · Male only
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Jan 7, 2011 · Synced Oct 29, 2026, 2:39 PM EDT